World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
42970
World Ranking
7310
National Ranking
3828

Alan F. List publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alan F. List sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 892 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alan F. List D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alan F. List sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2012 - Fellow, National Academy of Inventors

Overview

Alan F. List is affiliated with Precision BioSciences in the United States and has contributed extensively to the field of medicine, particularly focusing on hematology, genetics, immunology, molecular biology, and oncology. Their research intersects multiple subfields, with a strong emphasis on blood disorders and cancer-related conditions.

The scientist's main research topics include:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Inflammasome and immune disorders
  • CAR-T cell therapy research
  • Neutropenia and Cancer Infections
  • Immune cells in cancer
  • Acute Lymphoblastic Leukemia research

Their frequent publication venues reflect a focus on hematologic and oncological research. These include:

  • Blood
  • Leukemia
  • Journal of Clinical Oncology
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Among recent papers, Alan F. List has been connected to several notable works, such as:

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (2020), published in New England Journal of Medicine
  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes (2021), published in Journal of Clinical Oncology
  • TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype (2020), published in Blood
  • Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS (2020), published in Leukemia
  • Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes (2021), published in Blood Advances

Collaborative efforts with frequent co-authors include:

  • Eric Padron
  • Rami S. Komrokji
  • David A. Sallman
  • Mikkael A. Sekeres
  • Amy E. DeZern

Alan F. List was recognized as a Fellow of the National Academy of Inventors in 2012, reflecting a professional standing that intersects research and innovation. Their work spans over a hundred publications primarily focused on medical research, contributing significantly to the understanding and treatment of hematologic malignancies and associated immune disorders.

Best Publications

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    R H Collins;O Shpilberg;W R Drobyski;D L Porter

  • Efficacy of lenalidomide in myelodysplastic syndromes.

    Alan List;Sandy Kurtin;Denise J. Roe;Andrew Buresh

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004, Using Data From the NAACCR and SEER Programs

    Dana E. Rollison;Nadia Howlader;Martyn T. Smith;Sara S. Strom

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

    Alan F. List;Kenneth J. Kopecky;Cheryl L. Willman;David R. Head

  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

    Hagop Kantarjian;Susan O'Brien;Farhad Ravandi;Jorge Cortes

  • Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia

    C L Willman;C E Sever;M G Pallavicini;H Harada

  • Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

    William T. Bellamy;Lynne Richter;Davuud Sirjani;Concepcion Roxas

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

    Andres Jerez;Michael J. Clemente;Hideki Makishima;Hanna Koskela

  • Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

    A F List;C Spier;J Greer;S Wolff

  • First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

    Eric J. Feldman;Jeffrey E. Lancet;Jonathan E. Kolitz;Ellen K. Ritchie

  • Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A

    Anna M. Jankowska;Hideki Makishima;Ramon V. Tiu;Hadrian Szpurka

  • Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia

    Alan F. List;Catherine S. Spier;Thomas M. Grogan;Cynthia Johnson

  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

    David A Sallman;Amy E DeZern;Guillermo Garcia-Manero;David P Steensma

  • The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

    Ashley A. Basiorka;Kathy L. McGraw;Erika A. Eksioglu;Xianghong Chen

  • The thalidomide saga.

    Magda Melchert;Alan List

Frequent Co-Authors

Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic
Jaroslaw P. Maciejewski
Jaroslaw P. Maciejewski Cleveland Clinic
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Ghulam J. Mufti
Ghulam J. Mufti King's College London
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Sheng Wei
Sheng Wei University of South Florida
David P. Steensma
David P. Steensma Harvard University
Eva Hellström-Lindberg
Eva Hellström-Lindberg Karolinska University Hospital
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Amit Verma
Amit Verma Albert Einstein College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn't always require attending a traditional medical school. There are many flexible online options that can help you get started in the healthcare field or advance your current career. Exploring affordable online FNP programs is a great way to become a Family Nurse Practitioner, a highly respected and in-demand profession in the U.S.

For those who want to start in nursing, you can look into affordable nursing programs that allow you to study online at your own pace. If you are already a registered nurse and want to enhance your credentials, the cheapest RN to BSN program can help you open more career opportunities and increase your earning potential.

Interested in research or teaching at the highest levels? The cheapest PhD nursing programs online offer a cost-effective route to advanced expertise and leadership roles. All of these online pathways provide flexible, affordable alternatives for those looking to build a rewarding healthcare career in the USA.

Best Scientists Citing Alan F. List

Trending Scientists

Recently Published Articles